Reduced pharmacy resource utilization associated with raltitrexed treatment of advanced colorectal cancer

Journal of Oncology Pharmacy Practice

Volumn 3, Issue 1, 1997, Pages 24-30

  Summerhayes, Maxwell ^a   Wanklyn, Steven J ^a   Shakespeare, Roselyn A ^a   Lovell, Jacqueline ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

5 fluorouracil; Cancer; Chemotherapy; Colorectal; Pharmacaeconomics; Raltitrexed

Indexed keywords

EID: 0001832424     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/107815529700300104     Document Type: Article

References (17)

1. Cohen AM, Minsky BD, Schilsky RL Colon cancer. In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 4th ed. Philadelphia: J.B. Lippincott; 1993:929-977.
2. Souhami R., Tobias J. Tumours of the small and large bowel. In: Cancer and Its Management, 2nd ed. Oxford: Blackwell Science; 1995:305-316.
3. Moertel CG, Reitemeier RJ Chemotherapy of advanced gastrointestinal cancer: introduction. In: Advanced Gastrointestinal Cancer: Clinical Management and Chemotherapy. New York: Harper and Row; 1969:73-76.
4. Carter SK Large bowel cancer: the current status of treatment. J Natl Cancer Inst. 1976;56:3-10.
5. Moertel CG Large bowel. In: Holland JF, Frei E, eds. Cancer Medicine. Philadelphia: Lea and Febiger; 1973 :1497-1626.
6. ACCMP.Advanced Colorectal Cancer Metastasis Project. J Clin Oncol. 1992;10:896-903.
7. Poon MA, O'Connell MJ, Moertel CG,et al.Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol. 1989;7:1407-1418.
8. Poon MA, O'Connell MJ, Wieand HS,et al.Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol. 1991;9:1967-1992.
9. De Gramont A., Krulik M., Cady J.,et al.High-dose leucovorin and 5-fluorouracil bolus and infusion in advanced colorectal cancer. EurJ Clin Oncol. 1988;24:1499-1503.
10. Machover D., Goldschmidt E., Chollet P.,et al.Treatment of advanced colorectal and gastric adenocarcinoma with 5-fluorouracil and high dose folinic acid. J Clin Oncol. 1986;4:685-696.
11. Ahlgren JD Protracted infusional schedules of fluorouracil in colorectal cancer versus fluorouracil with modulators: differences and similarities. J Infus Chemother. 1992;2:128-137.
12. Lokich JJ, Ahlgren JD, Gullo JJ,et al.A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J Clin Oncol. 1989; 7:1419-1426.
13. Jackman AL, Jones TR, Calvert HA Thymidilate synthetase inhibitors: Experimental and clinical aspects. In: Muggia FM, ed. Experimental and Clinical Progress in Cancer Chemotherapy. Boston: Martinus Nijhoff; 1985:155-210.
14. Clarke SJ, Jackman AL, Judson IR The history of the development and clinical use of CB 3717 and ICI D1694. Adv Exp Med Biol. 1993;339:277-287.
15. Zalcberg J., Cunningham D., Green M.,et al.The final results of a large phase II study of the potent thymidilate synthase (TS) inhibitor 'Tomudex' (ZD1694) in advanced colorectal cancer. Proc Am Soc Clin Oncol. 1995;14:204.
16. Cunningham D., Zalcberg JR,et al.'Tomudex' (ZD 1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer. 1995 :31A(No. 12);1945-1954.
17. Ross P.Heron J., Cunningham D. Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Eur J Cancer. 1996;32A(Suppl. 5):S13-S17.